Tovetumab

Drug Profile

Tovetumab

Alternative Names: Anti-PDGFRa MAb - MedImmune; MEDI-575

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cambridge Antibody Technology
  • Developer MedImmune
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Platelet-derived growth factor alpha receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Glioblastoma; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 01 May 2013 MedImmune completes a phase II trial in Glioblastoma (recurrent disease) in USA (NCT01268566)
  • 21 Mar 2013 Discontinued - Phase-I for Solid tumours (late-stage disease) in Japan (IV)
  • 21 Mar 2013 Discontinued - Phase-I/II for Non-small cell lung cancer (combination therapy, first-line therapy, late-stage disease) in USA, Canada, Hungary and Poland (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top